97P Cost-effectiveness of TTFields in addition to standard systemic therapy for stage IV non-small cell lung cancer patients following progression on or after platinum-based chemotherapy

Tumor Treating Fields (TTFields) + standard therapy (investigator's choice of docetaxel or immune checkpoint inhibitor ICI) significantly prolonged overall survival compared to standard therapy alone in patients with stage IV non-small cell lung cancer (NSCLC) following progression on or after platinum-based therapy. This study aims to estimate the cost-effectiveness of adding TTFields to standard therapy. A three-state (stable disease, progressive disease, and death) partitioned survival model was developed from a US payer perspective over a lifetime time horizon. Results from the phase III randomized LUNAR study (TTFields + standard therapy compared to standard therapy alone) were used to estimate long-term overall survival and progression-free survival using parametric extrapolation. A subgroup analysis examined TTFields with docetaxel and an ICI separately. Previously published utilities were used to calculate quality-adjusted life-years (QALYs). Treatment, administration, monitoring, and adverse event costs were sourced from the published fee schedules and MediSpan. Costs and benefits were discounted at 3% per year. Patients treated with TTFields + standard therapy had a mean lifetime survival of 2. 44 years (2. 17 discounted) compared to 1. 31 (1. 26 discounted) for standard therapy-alone. QALYs were 1. 78 (1. 58 discounted) for TTFields + standard therapy compared to 0. 97 (0. 93 discounted) for standard therapy-alone. Incremental total costs were 59, 217 (58, 505 discounted) higher for TTFields + standard therapy. The incremental cost-effectiveness ratio (ICER) was 89, 012 per QALY gained and 64, 316 per life-year gained. This analysis revealed that TTFields + standard therapy is cost-effective compared to standard therapy alone in patients with stage IV NSCLC after platinum-based chemotherapy. Table: 97PCost-effectiveness resultsTTFields + standard therapyStandard therapyDifferenceDiscounted costsTreatment68, 43113, 98654, 445Administration42432797 Supportive care5, 0392, 9222, 117Adverse events3, 5111, 6651, 846Total77, 40618, 90158, 505Discounted OutcomesLife-Years2. 171. 260. 91QALYs1. 580. 930. 66ICER (QALYs) 89, 012 Open table in a new tab